{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aflibercept+monthly", "query": { "intervention": "Aflibercept monthly" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 57, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aflibercept+monthly&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T15:24:46.247Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02214628", "title": "Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Age-related Macular Degeneration" ], "interventions": [ { "name": "Fovista® (anti-PDGF BB) plus anti-VEGF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ophthotech Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 101, "start_date": "2014-07", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2024-02-23", "last_synced_at": "2026-09-08T15:24:46.247Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02214628" }, { "nct_id": "NCT03585556", "title": "AAVCAGsCD59 for the Treatment of Wet AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Wet Age-related Macular Degeneration" ], "interventions": [ { "name": "Intravitreal anti-VEGF", "type": "DRUG" }, { "name": "Intravitreal AAVCAGsCD59", "type": "BIOLOGICAL" }, { "name": "Oral prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 25, "start_date": "2018-09-13", "completion_date": "2022-01-18", "has_results": false, "last_update_posted_date": "2025-03-30", "last_synced_at": "2026-09-08T15:24:46.247Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Worcester, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03585556" }, { "nct_id": "NCT01617148", "title": "Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Exudative Macular Degeneration" ], "interventions": [ { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rishi Singh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 26, "start_date": "2012-06", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2018-07-26", "last_synced_at": "2026-09-08T15:24:46.247Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01617148" }, { "nct_id": "NCT02457026", "title": "Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "Aflibercept", "type": "DRUG" }, { "name": "Triamcinolone Acetonide", "type": "DRUG" }, { "name": "Verteporfin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 0, "start_date": "2016-01", "completion_date": "2018-01", "has_results": false, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-09-08T15:24:46.247Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02457026" }, { "nct_id": "NCT01414153", "title": "Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Exudative Age-related Macular Degeneration" ], "interventions": [ { "name": "4.0 mg iSONEP", "type": "DRUG" }, { "name": "0.5 mg iSONEP", "type": "DRUG" }, { "name": "0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea", "type": "DRUG" }, { "name": "sham injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lpath, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 158, "start_date": "2012-08", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-10-17", "last_synced_at": "2026-09-08T15:24:46.247Z", "location_count": 44, "location_summary": "Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01414153" }, { "nct_id": "NCT02559180", "title": "Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetic Retinopathy", "Macular Edema" ], "interventions": [ { "name": "aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rishi Singh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2015-10", "completion_date": "2020-12", "has_results": true, "last_update_posted_date": "2023-03-30", "last_synced_at": "2026-09-08T15:24:46.247Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02559180" }, { "nct_id": "NCT02387957", "title": "A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "Fovista®", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "ranibizumab", "type": "DRUG" }, { "name": "aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ophthotech Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 63, "start_date": "2016-04-26", "completion_date": "2017-01", "has_results": true, "last_update_posted_date": "2024-10-30", "last_synced_at": "2026-09-08T15:24:46.247Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "New London", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02387957" }, { "nct_id": "NCT05063734", "title": "A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus", "Diabetic Retinopathy", "Diabetic Macular Edema" ], "interventions": [ { "name": "THR-687 dose level 1", "type": "DRUG" }, { "name": "THR-687 dose level 2", "type": "DRUG" }, { "name": "THR-687 selected dose level", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oxurion", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2021-08-27", "completion_date": "2022-06-29", "has_results": true, "last_update_posted_date": "2023-08-18", "last_synced_at": "2026-09-08T15:24:46.247Z", "location_count": 18, "location_summary": "Huntington Beach, California • Pasadena, California • Sacramento, California + 15 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Elmhurst", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05063734" }, { "nct_id": "NCT03917472", "title": "Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Brolucizumab", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 517, "start_date": "2019-07-17", "completion_date": "2021-03-24", "has_results": true, "last_update_posted_date": "2022-08-12", "last_synced_at": "2026-09-08T15:24:46.247Z", "location_count": 74, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 66 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03917472" }, { "nct_id": "NCT03468296", "title": "Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "Intravitreal Aflibercept Injection 2mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tennessee Retina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 22, "start_date": "2018-04", "completion_date": "2019-07", "has_results": false, "last_update_posted_date": "2018-04-20", "last_synced_at": "2026-09-08T15:24:46.247Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03468296" } ] }